Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Redvax

M&A STATUS
M&A LATEST DEAL TYPE
Description

Operator of a biopharmaceutical company in Sweden. The company develops multi-component virus-like particles (VLPs) and other protein assemblies for vaccine development in the field of Cytomegalovirus (CMV).

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Acquirer
Primary Office
  • Wagistrasse 23
  • Schlieren
  • 8952 Zurich
  • Switzerland
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Redvax’s full profile, request a free trial.

Redvax Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 05-Jan-2015 Completed Pre-Clinical Trials
1. Early Stage VC Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Redvax Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Redalpine Venture Partners Venture Capital Minority 000 0000 000000 0

Redvax Executive Team (1)

Name Title Board
Seat
Contact
Info
Christian Schaub Managing Director